2005
DOI: 10.1002/cncr.20862
|View full text |Cite
|
Sign up to set email alerts
|

Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era

Abstract: BACKGROUND Recent breakthroughs regarding gastrointestinal stromal tumors (GIST) and their pathogenesis have redefined diagnostic criteria and have led to the development of molecularly targeted drug therapy. New treatment options mandate more accurate information regarding the incidence, prevalence, clinical behavior, and prognostic factors of GIST. METHODS All patients (n = 1460) who potentially had GIST diagnosed from 1983 to 2000 in western Sweden (population, 1.3–1.6 million) were reviewed, and 288 patien… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

29
819
9
77

Year Published

2007
2007
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 1,155 publications
(955 citation statements)
references
References 22 publications
29
819
9
77
Order By: Relevance
“…Gastrointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract with an incidence of approximately 0.65 -1.5 cases per 100'000 inhibitants (1)(2)(3)(4)(5)(6). The most frequently affected sites are stomach and small intestine, but GISTs may also develop in any other part of the GI tract, peritoneum and retroperitoneum.…”
Section: Introductionmentioning
confidence: 99%
“…Gastrointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract with an incidence of approximately 0.65 -1.5 cases per 100'000 inhibitants (1)(2)(3)(4)(5)(6). The most frequently affected sites are stomach and small intestine, but GISTs may also develop in any other part of the GI tract, peritoneum and retroperitoneum.…”
Section: Introductionmentioning
confidence: 99%
“…[1][2][3][4] This corresponds to between 3300 and 6000 new cases per year in the United States. Following surgical resection, GISTs often recur locally, spread diffusely throughout the serosal surfaces of the abdomen, and/or metastasize to the liver.…”
mentioning
confidence: 99%
“…The uncertain prognosis of GIST, both before (Nilsson et al, 2005) and after (Kosmadakis et al, 2005) imatinib treatment, indicate the need for the search of other molecular prognostication biomarkers. GIST are highly vascularised neoplasms and VEGF-A is a major antiangiogenic therapeutic target (Ferrara and Kerbel, 2005).…”
Section: Discussionmentioning
confidence: 99%